<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24705493</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>09</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-0020</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>123</Volume>
            <Issue>21</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>May</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Blood</Title>
          <ISOAbbreviation>Blood</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas.</ArticleTitle>
        <Pagination>
          <StartPage>3230</StartPage>
          <EndPage>3238</EndPage>
          <MedlinePgn>3230-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1182/blood-2014-03-537506</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic neurological syndromes (PNSs) rarely associate with Hodgkin lymphoma (HL) and non-HLs (NHLs). Except for paraneoplastic cerebellar degeneration (PCD) in HL and dermato/ polymyositis in both HL and NHL, other PNSs are uncommon and have only been reported as isolated case reports or short series. There are several important differences in PNSs when occurring in association with HL and NHL compared with those associated with solid tumors. First, some PNSs such as sensory neuronopathy or Lambert-Eaton myasthenic syndrome rarely occur in lymphomas, whereas others, such as granulomatous angiitis, are only described in HL. Second, onconeural antibodies are absent in most PNSs associated with lymphomas with the exceptions of Tr (δ/notch-like epidermal growth factor-related receptor) in PCD and mGluR5 in limbic encephalitis (LE). The antigens recognized by these antibodies are not expressed in lymphoma cells, suggesting the tumor itself does not trigger the PNS. Third, unlike patients with solid tumors in patients with lymphoma, the PNSs often develops at advanced stages of the disease. Furthermore, the type and frequency of PNSs are different between HL and NHL; whereas LE and PCD occur almost exclusively in patients with HL, sensorimotor neuropathies and dermatomyositis are more frequent in NHL.</AbstractText>
          <CopyrightInformation>© 2014 by The American Society of Hematology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Graus</LastName>
            <ForeName>Francesc</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-8924-8322</Identifier>
            <AffiliationInfo>
              <Affiliation>Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Department of Neurology, Hospital Clinic, Barcelona, Spain;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ariño</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Department of Neurology, Hospital Clinic, Barcelona, Spain;</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dalmau</LastName>
            <ForeName>Josep</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, PA; and Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 NS077851</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01NS077851</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Blood</MedlineTA>
        <NlmUniqueID>7603509</NlmUniqueID>
        <ISSNLinking>0006-4971</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006689" MajorTopicYN="N">Hodgkin Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008228" MajorTopicYN="N">Lymphoma, Non-Hodgkin</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020361" MajorTopicYN="N">Paraneoplastic Syndromes, Nervous System</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020293" MajorTopicYN="N">Vasculitis, Central Nervous System</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>9</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24705493</ArticleId>
        <ArticleId IdType="pmc">PMC4046430</ArticleId>
        <ArticleId IdType="doi">10.1182/blood-2014-03-537506</ArticleId>
        <ArticleId IdType="pii">S0006-4971(20)40169-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darnell RB, Posner JB.  Oxford, UK: Oxford University Press; 2011. Paraneoplastic Syndromes. Contemporary Neurology Series 79. pp. 1–482.</Citation>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924–928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18032743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Höftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS ONE. 2013;8(3):e60438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607586</ArticleId>
            <ArticleId IdType="pubmed">23536908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernal F, Shams’ili S, Rojas I, et al.  Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology. 2003;60(2):230–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12552036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaff E, Maat P, Hulsenboom E, et al.  Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol. 2012;71(6):815–824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22447725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, Dalmau J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380–390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718498</ArticleId>
            <ArticleId IdType="pubmed">22710628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, McCracken L, Gabilondo I, et al.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3563251</ArticleId>
            <ArticleId IdType="pubmed">23290630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai M, Huijbers MG, Lancaster E, et al.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3086669</ArticleId>
            <ArticleId IdType="pubmed">20580615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, Maddison P, Sont JK, et al.  Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902–908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21245427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, Lai M, Peng X, et al.  Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irani SR, Pettingill P, Kleopa KA, et al.  Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22473710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai M, Hughes EG, Peng X, et al.  AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4):424–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677127</ArticleId>
            <ArticleId IdType="pubmed">19338055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Gelfand JM, Gresa-Arribas N, et al.  Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73(1):120–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3563722</ArticleId>
            <ArticleId IdType="pubmed">23225603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sillevis Smitt P, Kinoshita A, De Leeuw B, et al.  Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342(1):21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10620645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al.  Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77(18):1698–1701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208954</ArticleId>
            <ArticleId IdType="pubmed">22013185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briani C, Vitaliani R, Grisold W, et al.  PNS Euronetwork. Spectrum of paraneoplastic disease associated with lymphoma. Neurology. 2011;76(8):705–710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21339498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carr I. The Ophelia syndrome: memory loss in Hodgkin’s disease. Lancet. 1982;1(8276):844–845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6122069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duyckaerts C, Derouesne C, Signoret JL, Gray F, Escourolle R, Castaigne P. Bilateral and limited amygdalohippocampal lesions causing a pure amnesic syndrome. Ann Neurol. 1985;18(3):314–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3931539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deodhare S, O’Connor P, Ghazarian D, Bilbao JM. Paraneoplastic limbic encephalitis in Hodgkin’s disease. Can J Neurol Sci. 1996;23(2):138–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8738928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenbaum T, Gärtner J, Körholz D, et al.  Paraneoplastic limbic encephalitis in two teenage girls. Neuropediatrics. 1998;29(3):159–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9706628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kung S, Mueller PS, Geda YE, Krahn LE. Delirium resulting from paraneoplastic limbic encephalitis caused by Hodgkin’s disease. Psychosomatics. 2002;43(6):498–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12444235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfliegler G, Pósán E, Glaub D, Telek B, Rak K. Hodgkin’s disease and memory loss: another case of the Ophelia syndrome. Br J Haematol. 1990;74(2):232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2317460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinohara T, Kojima H, Nakamura N, et al.  Pathology of pure hippocampal sclerosis in a patient with dementia and Hodgkin’s disease: the Ophelia syndrome. Neuropathology. 2005;25(4):353–360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16382785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olmos D, Rueda A, Jurado JM, Alba E. Presentation of Hodgkin’s lymphoma with Ophelia syndrome. J Clin Oncol. 2007;25(13):1802–1803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17470872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hentschke S, Malzfeldt E, Salwender HJ, Braumann D, Stang A, Hentschke M. Hu-antibody positive limbic encephalitis in a patient with Hodgkin lymphoma. Leuk Lymphoma. 2008;49(12):2374–2376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19052989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zandi MS, Irani SR, Follows G, Moody AM, Molyneux P, Vincent A. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology. 2009;73(23):2039–2040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19996080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laffon M, Giordana C, Almairac F, Benchetrit M, Thomas P. Anti-Hu-associated paraneoplastic limbic encephalitis in Hodgkin lymphoma. Leuk Lymphoma. 2012;53(7):1433–1434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22136379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mat A, Adler H, Merwick A, et al.  Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology. 2013;80(14):1349–1350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3656459</ArticleId>
            <ArticleId IdType="pubmed">23486886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernard P, Vinzio S, Talarmin F, Kadouri A, Flocard F. [Hodgkin’s disease manifesting as paraneoplastic limbic encephalitis]. Rev Med Interne. 2003;24(4):257–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12706783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epaulard O, Courby S, Pavese P, et al.  Paraneoplastic acute diffuse encephalitis revealing Hodgkin’s disease. Leuk Lymphoma. 2004;45(12):2509–2512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15621769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mollier-Saliner J, Thouvenin S, Darteyre S, et al.  [Paraneoplastic limbic encephalitis: 2 pediatric cases]. Arch Pediatr. 2013;20(4):386–390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23474034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mihara M, Sugase S, Konaka K, et al.  The “pulvinar sign” in a case of paraneoplastic limbic encephalitis associated with non-Hodgkin’s lymphoma. J Neurol Neurosurg Psychiatry. 2005;76(6):882–884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739656</ArticleId>
            <ArticleId IdType="pubmed">15897519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dögel D, Beuing O, Koenigsmann M, Diete S. [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports]. Fortschr Neurol Psychiatr. 2008;76(1):41–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18189222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajappa S, Digumarti R, Immaneni SR, Parage M. Primary renal lymphoma presenting with paraneoplastic limbic encephalitis. J Clin Oncol. 2007;25(24):3783–3785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17704429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markert A, May A, Weber J, Rottenburger C, Rauer S, Veelken H. Bilateral renal lymphoma after paraneoplastic limbic encephalitis. J Clin Oncol. 2009;27(7):1142–1144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19124810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thuerl C, Müller K, Laubenberger J, Volk B, Langer M. MR imaging of autopsy-proved paraneoplastic limbic encephalitis in non-Hodgkin lymphoma. AJNR Am J Neuroradiol. 2003;24(3):507–511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12637305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seeley WW, Marty FM, Holmes TM, et al.  Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007;69(2):156–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17620548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH. Primary angiitis of the CNS. Lancet Neurol. 2011;10(6):561–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21601163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delobel P, Brassat D, Danjoux M, et al.  Granulomatous angiitis of the central nervous system revealing Hodgkin’s disease. J Neurol. 2004;251(5):611–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15164198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosen CL, DePalma L, Morita A. Primary angiitis of the central nervous system as a first presentation in Hodgkin’s disease: a case report and review of the literature. Neurosurgery. 2000;46(6):1504–1508, discussion 1508-1510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10834654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehy N, Sheehan K, Brett F, Kay E, Grogan L, Delanty N. Hodgkins disease presenting with granulomatous angiitis of the central nervous system. J Neurol. 2003;250(1):112–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12528007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Power DG, Mullholland PJ, Sheehy N, Farrell MA, Daly PA. Relapsing granulomatous angiitis of the central nervous system in a patient while in remission from Hodgkin lymphoma. Ir Med J. 2006;99(9):282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17144241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuehrer NE, Hammack JE, Morris JM, Kaufmann TJ, Giannini C. Teaching NeuroImages: granulomatous angiitis of the CNS associated with Hodgkin lymphoma. Neurology. 2011;77(19):e110–e111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22067969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Guennec L, Roos-Weil D, Mokhtari K, et al.  Granulomatous angiitis of the CNS revealing a Hodgkin lymphoma. Neurology. 2013;80(3):323–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23269593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams’ili S, Grefkens J, de Leeuw B, et al.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(Pt 6):1409–1418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ang LC, Zochodne DW, Ebers GC, Kaufmann JC, Vinters HV. Severe cerebellar degeneration in a patient with T-cell lymphoma. Acta Neuropathol. 1986;69(1-2):171–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3485877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodis DG, Liatsos GD, Moulakakis A, Pirounaki M, Tasidou A. Paraneoplastic cerebellar degeneration: initial presentation in a patient with anaplastic T-cell lymphoma, associated with ichthyosiform cutaneous lesions. Leuk Lymphoma. 2009;50(8):1369–1371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19544138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimazu Y, Minakawa EN, Nishikori M, et al.  A case of follicular lymphoma associated with paraneoplastic cerebellar degeneration. Intern Med. 2012;51(11):1387–1392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22687848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol. 1976;33(9):660–661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">962649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmau J, Valldeoriola F, et al.  Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol. 1997;74(1-2):55–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9119979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eiraku M, Hirata Y, Takeshima H, Hirano T, Kengaku M. Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem. 2002;277(28):25400–25407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11950833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sillevis Smitt P, Kinoshita A, De Leeuw B, et al.  Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342(1):21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10620645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marignier R, Chenevier F, Rogemond V, et al.  Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol. 2010;67(5):627–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20457964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammack JE, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin’s disease. Neurology. 1992;42(10):1938–1943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1407576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vigliani MC, Honnorat J, Antoine JC, et al.  PNS EuroNetwork. Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol. 2011;258(11):2058–2068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21559939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Toole O, Lennon VA, Ahlskog JE, et al.  Autoimmune chorea in adults. Neurology. 2013;80(12):1133–1144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3662307</ArticleId>
            <ArticleId IdType="pubmed">23427325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Platten M, Palmer-Toy DE, et al.  Chorea as a paraneoplastic complication of Hodgkin’s disease. J Neurooncol. 1998;36(2):185–190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9525818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S, Tuite P, Adler CH, et al.  Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002;51(5):625–630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12112110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord. 1995;10(1):22–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7885352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Graus F, Saiz A, Vilchez JJ Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(Pt 2):437–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11157570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducrocq X, Petit J, Taillandier L, et al.  [Paraneoplastic opsoclonus-myoclonus syndrome revealing T-cell lymphoma]. Presse Med. 1999;28(7):330–333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10083874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar A, Lajara-Nanson WA, Neilson RW., Jr Paraneoplastic Opsoclonus-Myoclonus Syndrome: initial presentation of non-Hodgkins lymphoma. J Neurooncol. 2005;73(1):43–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15933816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabaldon-Torres L, Fernandez-Dominguez J, Salas-Felipe J, et al.  [Opsoclonus-myoclonus-ataxia syndrome: two anatomo-clinical case reports]. Rev Neurol. 2009;48(3):137–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19206061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kay CL, Davies-Jones GA, Singal R, Winfield DA. Paraneoplastic opsoclonus-myoclonus in Hodgkin’s disease. J Neurol Neurosurg Psychiatry. 1993;56(7):831–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1015072</ArticleId>
            <ArticleId IdType="pubmed">8331365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A, Robinson MT, McEvoy KM, et al.  Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2):230–238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22332190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whiteley AM, Swash M, Urich H. Progressive encephalomyelitis with rigidity. Brain. 1976;99(1):27–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">963529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKeon A, Martinez-Hernandez E, Lancaster E, et al.  Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol. 2013;70(1):44–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718477</ArticleId>
            <ArticleId IdType="pubmed">23090334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari P, Federico M, Grimaldi LM, Silingardi V. Stiff-man syndrome in a patient with Hodgkin’s disease. An unusual paraneoplastic syndrome. Haematologica. 1990;75(6):570–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2098300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutmann B, Crivellaro C, Mitterer M, Zingerle H, Egarter-Vigl E, Wiedermann CJ. Paraneoplastic stiff-person syndrome, heterotopic soft tissue ossification and gonarthritis in a HLA B27-positive woman preceding the diagnosis of Hodgkin’s lymphoma. Haematologica. 2006;91(12 Suppl):ECR59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17194665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt C, Freilinger T, Lieb M, et al.  Progressive encephalomyelitis with rigidity and myoclonus preceding otherwise asymptomatic Hodgkin’s lymphoma. J Neurol Sci. 2010;291(1-2):118–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20110093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, McKeon A, Lennon VA, et al.  Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology. 2011;76(24):2089–2095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21670438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ojeda VJ. Necrotizing myelopathy associated with malignancy. A clinicopathologic study of two cases and literature review. Cancer. 1984;53(5):1115–1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6362838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray F, Hauw JJ, Escourolle R, Castaigne P. [Necrotic myelopathies and neoplastic pathologie. Three clinico-pathological cases (author’s transl)]. Rev Neurol (Paris) 1980;136(3):235–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6893368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes M, Ahern V, Kefford R, Boyages J. Paraneoplastic myelopathy at diagnosis in a patient with pathologic stage 1A Hodgkin disease. Cancer. 1992;70(6):1598–1600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1516011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson DW, Borsaru A. Case report: Lymphoma-related resolving paraneoplastic myelopathy with MRI correlation. Br J Radiol. 2008;81(964):e103–e105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18344265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Keime-Guibert F, Reñe R, et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138–1148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schold SC, Cho ES, Somasundaram M, Posner JB. Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol. 1979;5(3):271–287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">443760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan EP, Sandroni P, Pittock SJ, Inwards DJ, Jones LK., Jr Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma. Muscle Nerve. 2012;46(5):823–827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23055320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horwich MS, Cho L, Porro RS, Posner JB. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol. 1977;2(1):7–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">197875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-1990. A 45-year-old woman with Hodgkin’s disease and a neurologic disorder. N Engl J Med. 1990;322(8):531–543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2153932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maslovsky I, Volchek L, Blumental R, Ducach A, Lugassy G. Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin’s disease. Eur J Haematol. 2001;66(1):63–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11168510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh BC, Lim YM, Kwon YM, Khang SK, Kim KK. A case of Hodgkin’s lymphoma associated with sensory neuropathy. J Korean Med Sci. 2004;19(1):130–133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2822249</ArticleId>
            <ArticleId IdType="pubmed">14966355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plante-Bordeneuve V, Baudrimont M, Gorin NC, Gherardi RK. Subacute sensory neuropathy associated with Hodgkin’s disease. J Neurol Sci. 1994;121(2):155–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8158207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike H, Watanabe H, Sobue G. The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features. J Neurol Neurosurg Psychiatry. 2013;84(1):98–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22906617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Lieshout JJ, Wieling W, van Montfrans GA, et al.  Acute dysautonomia associated with Hodgkin’s disease. J Neurol Neurosurg Psychiatry. 1986;49(7):830–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1028911</ArticleId>
            <ArticleId IdType="pubmed">3746314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollenbeck R, Black BK, Peltier AC, et al.  Long-term treatment with rituximab of autoimmune autonomic ganglionopathy in a patient with lymphoma. Arch Neurol. 2011;68(3):372–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3725638</ArticleId>
            <ArticleId IdType="pubmed">21059985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horta E, McKeon A, Lennon VA, Benarroch EE. Reversible paraneoplastic tonic pupil with PCA-Tr IgG and Hodgkin lymphoma. Neurology. 2012;78(20):1620–1622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22551727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shepshelovich D, Shpilberg O, Lahav M, et al.  Hodgkin lymphoma and hypothermia: Case report and review of the literature. Acta Haematol. 2013;131(4):227–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24335335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallat JM, De Mascarel HA, Bordessoule D, et al.  Non-Hodgkin malignant lymphomas and peripheral neuropathies—13 cases. Brain. 1995;118(Pt 5):1233–1245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7496783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lisak RP, Mitchell M, Zweiman B, Orrechio E, Asbury AK. Guillain-Barré syndrome and Hodgkin’s disease: three cases with immunological studies. Ann Neurol. 1977;1(1):72–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">889291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi M, Kato K, Funakoshi K, Watanabe S, Toyoshima I. Neuropathology of paraneoplastic neuropathy with anti-disialosyl antibody. Muscle Nerve. 2005;32(2):216–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15937876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomita M, Koike H, Kawagashira Y, et al.  Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136(Pt 8):2563–2578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23884813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012;18(5):463–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23006953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh SJ. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin. 1997;15(4):849–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9367968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zivković SA, Ascherman D, Lacomis D. Vasculitic neuropathy—electrodiagnostic findings and association with malignancies. Acta Neurol Scand. 2007;115(6):432–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17511855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent D, Gombert B, Vital A, Vital C. A case of mononeuropathy multiplex with type II cryoglobulinemia, necrotizing vasculitis and low grade B cell lymphoma. Clin Neuropathol. 2007;26(1):28–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17290934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie I, Guillevin L, Menard JF, et al.  Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev. 2012;11(9):615–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22079677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol. 2010;22(6):627–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20827204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, et al.  Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21953614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve. 1995;18(7):715–719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7783761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caress JB, Abend WK, Preston DC, Logigian EL. A case of Hodgkin’s lymphoma producing neuromyotonia. Neurology. 1997;49(1):258–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9222201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rana SS, Ramanathan RS, Small G, Adamovich B. Paraneoplastic Isaacs’ syndrome: a case series and review of the literature. J Clin Neuromuscul Dis. 2012;13(4):228–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22622168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezania K, Soliven B, Baron J, Lin H, Penumalli V, van Besien K. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012;53(3):371–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21864038</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
